)
Zydus Lifesciences on Wednesday has obtained approval from the US well being regulator to market a generic diabetes drug within the US market.
Zydus Lifesciences on Wednesday has obtained approval from the US well being regulator to market a generic diabetes drug within the US market.
The corporate has obtained tentative approval from the US Meals and Drug Administration (USFDA) for Dapagliflozin Tablets in strengths of 5 mg and 10 mg, the drug agency stated in a press release.
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to food plan and train to enhance glycaemic management in adults with sort 2 diabetes mellitus.
The corporate stated the tablets can be manufactured at its formulation manufacturing facility at SEZ, Ahmedabad. As per the trade estimates, Dapagliflozin tablets had annual gross sales of USD 10,486.9 million within the US.
Zydus shares on Wednesday ended 0.23 per cent up at Rs 905 apiece on BSE.
(Aside from the headline, this story has not been edited by The press reporter employees.)
Finish of Article
)
)
)
&description=Zydus+Lifesciences+gets+US+FDA+approval+for+generic+diabetes+drug){kind=link}